**SUMMARY OF PRODUCT CHARACTERISTICS**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ANIMEC 0.8mg/ml Oral Solution for Sheep (IE, UK, EL, PL, ES)

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

**Active substance:**

Each ml contains:

Ivermectin 0.8mg

Excipient(s):

Benzyl Alcohol (E1519) 28.6mg

Butylhydroxyanisole (E320) 0.10 mg

 Propyl Gallate (E310) 0.10 mg

For a full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Oral Solution.

A transparent, yellow coloured solution.

**4. CLINICAL PARTICULARS**

**4.1 Target species**

Sheep

**4.2 Indications for use, specifying the target species**

For the treatment of infections with the following parasites:

Nematodes

Gastrointestinal roundworms (adult and fourth larval stage)

Haemonchus contortus

Teladorsagia circumcincta

Trichostrongylus spp.

Cooperia spp.

Nematodirus spp.

Including N. battus

Strongyloides papillosus

Chabertia ovina

 Lungworms(adult and fourth larval stage)

Dictyocaulus filaria

Arthropods

Nasal bot (all larval stages)

Oestrus ovis

**4.3 Contraindications**

Do not use in animals with known hypersensitivity to the active ingredient or any of the excipients.

**4.4 Special warnings for each target species**

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

• Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.

• Underdosing, which may be due to underestimation of body weight or misadministration of the product.

Resistance to ivermectin (an avermectin) has been reported in Teladorsagia in sheep and goats within the EU and it is common in Haemonchus in sheep outside the EU. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematode and recommendations on how to limit further selection for resistance to anthelmintics.

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

There is cross-resistance with other avermectins and with milbemycins.

**4.5 Special precautions for use**

i. Special precautions for use in animals

The timing of treatment should be based on epidemiological factors and should be customised for each individual farm. A dosing programme should be established by the veterinary surgeon.

Veterinary advice should be sought on appropriate dosing programmes and stock management to achieve adequate parasite control, and to reduce the likelihood of anthelmintic resistance developing. Veterinary advice should also be sought if the product does not achieve the desired clinical effect, as other diseases, nutritional disturbances or anthelmintic resistance might be involved.

 Avermectins may not be well tolerated in non-target species. Cases of intolerance resulting in fatalities have been reported in dogs, especially Collies, Old English Sheep Dogs and related breeds or crosses, and also in turtles/tortoises.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use. Avoid contact with skin and eyes.

Do not eat, drink or smoke while handling the product.

 Wear impervious gloves when handling or administering the product.

As absorption through skin can occur, in the event of accidental skin contact, wash the affected area immediately with soap and water.

If accidental eye exposure occurs, flush the eyes immediately with water.

iii. Other precautions

None known.

**4.6 Adverse reactions (frequency and seriousness)**

Some sheep may cough immediately after treatment. This passing response is of no consequence.

**4.7 Use during pregnancy, lactation or lay**

The veterinary medicinal product can be administered to ewes at any stage of pregnancy or lactation.

See Section 4.11

**4.8 Interaction with other medicinal products and other forms of interaction**

None known.

**4.9 Amounts to be administered and administration route**

For oral administration only.

The recommended dose rate is 0.2 mg ivermectin per kg bodyweight (corresponding to 2.5 ml per 10 kg bodyweight)

To ensure administration of a correct dose, body weight should be determined as accurately as possible. Accuracy of the dosing device should be checked.

If animals are to be treated collectively rather than individually they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- or over- dosing.

**4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

At doses up to 4 mg ivermectin per kg administered by stomach tube (20x the recommended dose level) undesirable toxic reactions occurred. Acute symptoms (ataxia, staggering gait, incoordination, depression) were observed at the dose rate of 8 mg/kg (40x the recommended dose level) during a study carried out on 4 animals. Twenty-four hours later, the animals showed only mild incoordination and depression.

Three days post dose all the animals were nearly normal. It is possible that the signs of toxaemia were due to the propylene glycol.

No antidote has been identified. Symptomatic treatment may be beneficial.

**4.11 Withdrawal periods**

Meat and offal: 10 days.

Milk: Do not use in lactating sheep producing milk for human consumption.

Sheep must not be treated within 60 days prior to the commencement of lactation, if milk is to be used for human consumption.

**5. PHARMACOLOGICAL PROPERTIES**

**Pharmacotherapeutic group:** Endectocides, avermectins,

**ATCvet code:** QP54AA01.

**5.1 Pharmacodynamic properties**

Ivermectin belongs to the avermectin family, which are a macrocyclic lactone group of endectocides. Compounds of the class bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. Compounds of this class may also interact with other ligand-gated chloride channels, such as those grated by the neurotransmitter gamma-aminobutyric acid (GABA).

The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels, the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier.

**5.2 Pharmacokinetic particulars**

The maximum plasma concentration is reached in 12 hours after oral administration and ranges from 6.3 to 17.9 ng/ml at the dose rate of 0.2 mg ivermectin per kg bodyweight. This concentration gradually decreases to range from 1.31 to 10.55 ng/ml 2 days post dose with a terminal half-life of 42.4 hours.

Ivermectin binds extensively to plasma proteins. Due to its high lipophilic nature, Ivermectin is extensively distributed. It tends to accumulate in fat tissue, which acts as a drug reservoir and the highest levels of Ivermectin are found in liver and fat. Ivermectin is only partially metabolized. Ivermectin is mainly eliminated in the faeces as unaltered drug and faecal excretion accounts for 90% of the dose administered with <2% of the dose excreted in urine. Ivermectin is also excreted by the mammary gland.

**Environmental Properties**

None known.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Butylhydroxyanisole (E320)

Propyl Gallate (E310)

Benzyl Alcohol (E1519)

Propylene Glycol

Disodium Edetate

Polysorbate 80

Disodium Hydrogen Phosphate Dihydrate

Sodium Dihydrogen Phosphate Monohydrate

Purified Water

**6.2 Incompatibilities**

None known.

**6.3 Shelf life of the veterinary medicinal product as packaged for sale.**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the container: 18 months.

**6.4. Special precautions for storage**

Do not store above 30ºC.

**6.5 Nature and composition of immediate packaging**

White flat-bottomed flexi packs (1L, 2.5L, 5L and 6L (5L + 1L)) composed of high density polyethylene container, with a 38 mm tamper evident polypropylene cap.

Standard containers (jerri-cans) (1L, 2.5L, 5 L and 10L ) composed of high density polyethylene container, with tamper evident polyethylene cap.

Pack sizes (flexi pack): 1, 2.5 , 5L and 6L (5L+1L)

Pack sizes (jerri-cans): 1, 2.5, 5L and 10 Litre

Not all pack sizes may be marketed.

**6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

 EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE.

 Do not contaminate surface waters or ditches with product or used container.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceutical Manufacturing Limited

Loughrea

Co. Galway

Ireland

**8. MARKETING AUTHORISATION NUMBER**

**Vm** 08749/4027

**9. DATE OF FIRST AUTHORISATION**

**Date:** 08 July 2010

**10. DATE OF REVISION OF THE TEXT**

**Date:** October 2014



Approved: 01 December 2014